Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6).
Gabriel RinnerthalerSimon Peter GampenriederAndreas PetzerMichael HubalekEdgar PetruMargit SandholzerJohannes AndelMarija BalicThomas MelchardtCornelia Hauser-KronbergerClemens A SchmittHanno UlmerRichard GreilPublished in: Therapeutic advances in medical oncology (2021)
The combination of capecitabine and bendamustine shows promising efficacy and moderate toxicity. Further evaluation of this drug combination is warranted.The clinical trial AGMT MBC-6 was registered at ClinicalTrials.gov, (https://clinicaltrials.gov/; identifier: NCT01891227).